<?xml version="1.0" encoding="utf-8"?>
      <?xml-stylesheet type="text/xsl" href="/xslt/RssDisplay.xslt" media="screen"?>
  <rss version="2.0"><channel><title>MedWire News - General oncology</title><link>http://www.medwirenews.com/46/General_oncology.html</link><description>The latest news on the prevention, detection, diagnosis, and prognosis of cancer, and treatment modalities including chemotherapy, surgery, radiotherapy, and hormone therapy.</description><language>en</language><pubDate>Sun, 19 May 2013 14:03:14 GMT</pubDate><copyright>Current Medicine Group 2013 www.currentmedicinegroup.com</copyright><ttl>60</ttl><item><title><![CDATA[History of statin use lowers prostate cancer mortality]]></title><description><![CDATA[Research shows that men with prostate cancer have a significantly reduced risk for death if they took statins prior to their diagnosis.]]></description><link>http://www.medwirenews.com/46/104410/General_oncology/History_of_statin_use_lowers_prostate_cancer_mortality.html</link><guid isPermaLink="true">http://www.medwirenews.com/46/104410/General_oncology/History_of_statin_use_lowers_prostate_cancer_mortality.html</guid><pubDate>Mon, 13 May 2013 00:00:00 GMT</pubDate></item><item><title><![CDATA[Excess deaths among seminoma patients persist]]></title><description><![CDATA[US research shows that men diagnosed with stage I seminoma since the advent of contemporary radiotherapy have a significantly increased risk for all-cause mortality compared with the overall population, despite being unlikely to die from testicular cancer itself.]]></description><link>http://www.medwirenews.com/46/104411/General_oncology/Excess_deaths_among_seminoma_patients_persist.html</link><guid isPermaLink="true">http://www.medwirenews.com/46/104411/General_oncology/Excess_deaths_among_seminoma_patients_persist.html</guid><pubDate>Mon, 13 May 2013 00:00:00 GMT</pubDate></item><item><title><![CDATA[Thalidomide fails to boost mesothelioma outcomes]]></title><description><![CDATA[Adding maintenance thalidomide to standard first-line chemotherapy does not improve outcomes among patients with malignant pleural or peritoneal mesothelioma, study findings indicate.
]]></description><link>http://www.medwirenews.com/46/104381/General_oncology/Thalidomide_fails_to_boost_mesothelioma_outcomes.html</link><guid isPermaLink="true">http://www.medwirenews.com/46/104381/General_oncology/Thalidomide_fails_to_boost_mesothelioma_outcomes.html</guid><pubDate>Wed, 08 May 2013 00:00:00 GMT</pubDate></item><item><title><![CDATA[S-1 combination regimen effective for NSCLC]]></title><description><![CDATA[Researchers suggest that combined therapy with the fluoropyrimidine S-1, carboplatin, and bevacizumab followed by maintenance therapy with S-1 and bevacizumab  should be first-line treatment for patients with advanced non-squamous non-small-cell lung cancer. ]]></description><link>http://www.medwirenews.com/46/104382/General_oncology/S-1_combination_regimen_effective_for_NSCLC.html</link><guid isPermaLink="true">http://www.medwirenews.com/46/104382/General_oncology/S-1_combination_regimen_effective_for_NSCLC.html</guid><pubDate>Wed, 08 May 2013 00:00:00 GMT</pubDate></item><item><title><![CDATA[Gene fusion reduces NSCLC patient survival]]></title><description><![CDATA[<I>ROS1</I> fusions predict a poor outcome in Chinese patients with non-small-cell lung cancer, study findings suggest.
]]></description><link>http://www.medwirenews.com/46/104383/General_oncology/Gene_fusion_reduces_NSCLC_patient_survival.html</link><guid isPermaLink="true">http://www.medwirenews.com/46/104383/General_oncology/Gene_fusion_reduces_NSCLC_patient_survival.html</guid><pubDate>Wed, 08 May 2013 00:00:00 GMT</pubDate></item><item><title><![CDATA[Hsp90 inhibitor shows NSCLC promise]]></title><description><![CDATA[Treatment with a heatshock protein 90 inhibitor may induce loss of <I>EML4-AKL</I> expression in non-small cell lung cancer cells, preliminary results suggest.
]]></description><link>http://www.medwirenews.com/46/104384/General_oncology/Hsp90_inhibitor_shows_NSCLC_promise.html</link><guid isPermaLink="true">http://www.medwirenews.com/46/104384/General_oncology/Hsp90_inhibitor_shows_NSCLC_promise.html</guid><pubDate>Wed, 08 May 2013 00:00:00 GMT</pubDate></item><item><title><![CDATA[TKI resistance markers found for NSCLC patients]]></title><description><![CDATA[Korean scientists have identified several genetic markers that may explain lack of response to tyrosine kinase inhibitor therapy in patients with epidermal growth factor receptor-activating, non-small-cell lung cancer.]]></description><link>http://www.medwirenews.com/46/104385/General_oncology/TKI_resistance_markers_found_for_NSCLC_patients.html</link><guid isPermaLink="true">http://www.medwirenews.com/46/104385/General_oncology/TKI_resistance_markers_found_for_NSCLC_patients.html</guid><pubDate>Wed, 08 May 2013 00:00:00 GMT</pubDate></item><item><title><![CDATA[<i>KRAS</i> oncogene substitutions may be predictive in lung adenocarcinoma]]></title><description><![CDATA[Researchers have found that certain <I>KRAS </I>oncogene substitutions may have predictive value in lung adenocarcinoma.
]]></description><link>http://www.medwirenews.com/46/104386/General_oncology/KRAS_oncogene_substitutions_may_be_predictive_in_lung_adenocarcinoma.html</link><guid isPermaLink="true">http://www.medwirenews.com/46/104386/General_oncology/KRAS_oncogene_substitutions_may_be_predictive_in_lung_adenocarcinoma.html</guid><pubDate>Wed, 08 May 2013 00:00:00 GMT</pubDate></item><item><title><![CDATA[Burden of symptoms could guide NSCLC pemetrexed use]]></title><description><![CDATA[Symptom burden and performance status may help identify the patients with non-squamous non-small-cell lung cancer who are likely to respond to maintenance pemetrexed therapy, phase III trial findings suggest.]]></description><link>http://www.medwirenews.com/46/104387/General_oncology/Burden_of_symptoms_could_guide_NSCLC_pemetrexed_use.html</link><guid isPermaLink="true">http://www.medwirenews.com/46/104387/General_oncology/Burden_of_symptoms_could_guide_NSCLC_pemetrexed_use.html</guid><pubDate>Wed, 08 May 2013 00:00:00 GMT</pubDate></item><item><title><![CDATA[Active surveillance encouraged for very-low-risk prostate cancer in under 55s]]></title><description><![CDATA[A study of US servicemen shows that, despite being eligible for active surveillance, the overwhelming majority of young men diagnosed with very-low-risk prostate cancer opt for immediate treatment.]]></description><link>http://www.medwirenews.com/46/104405/General_oncology/Active_surveillance_encouraged_for_very-low-risk_prostate_cancer_in_under_55s.html</link><guid isPermaLink="true">http://www.medwirenews.com/46/104405/General_oncology/Active_surveillance_encouraged_for_very-low-risk_prostate_cancer_in_under_55s.html</guid><pubDate>Mon, 06 May 2013 00:00:00 GMT</pubDate></item></channel></rss>